UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 373

Sortiert nach

Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse

Annals of oncology, 2015-06, Vol.26 (6), p.1155-1160

2015

Link zum Volltext

Verfügbarkeit prüfen

Gestational Trophoblastic Disorders: An Update in 2015

Geburtshilfe und Frauenheilkunde, 2015-10, Vol.75 (10), p.1043-1050

2015

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network

Geburtshilfe und Frauenheilkunde, 2015-01, Vol.75 (1), p.41-50

2015

Link zum Volltext

Verfügbarkeit prüfen

Vulvakarzinom in der Schwangerschaft

Onkologie (Heidelberg, Germany), 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11112-e11112

2011

Link zum Volltext

Verfügbarkeit prüfen

Expression of embryonic stem cell factor Sox2 in serous ovarian carcinomas

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5039-5039

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-01-13: A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector™ enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-01-13

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of bisphosphonates on human osteoblasts as an important constituent of the bone marrow microenvironment

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13620-e13620

2010

Link zum Volltext

Verfügbarkeit prüfen

Bone marrow carcinosis in breast cancer: Clinical presentation, treatment, and prognosis—A single institution review of 22 cases

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e11514-e11514

2010

Link zum Volltext

Verfügbarkeit prüfen

Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1038-1038

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS5-03-GS5-03

2019

Link zum Volltext

Verfügbarkeit prüfen

The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1070-1070

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-01-14: A nomogram to predict the likelihood of axillary non-sentinel lymph node metastases in sentinel lymph node positive primary breast cancer patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-01-14

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-37

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-22

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-11-02-OT1-11-02

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-20

2018

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5093-5093

2011

Link zum Volltext

Verfügbarkeit prüfen

Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.530-530

2011

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1153-1153

2010

Link zum Volltext

Verfügbarkeit prüfen

Influence of primary systemic therapy on minimal residual disease in primary breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.647-647

2010

Link zum Volltext

Verfügbarkeit prüfen

Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS114-TPS114

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-11-07

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD1-02-PD1-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-09

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 373

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(368)
Mit Volltextzugriff
(369)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Geburtshilfe Und Frauenheilkunde
(74)
Journal Of Clinical Oncology
(72)
Cancer Research
(32)
Annals Of Oncology
(15)
Breast Cancer Research And Treatment
(9)
European Journal Of Cancer
(8)
Breast Care
(7)
Bmc Cancer
(5)
Breast
(5)
Clinical Cancer Research
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse

Gestational Trophoblastic Disorders: An Update in 2015

Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network

Vulvakarzinom in der Schwangerschaft

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay

Expression of embryonic stem cell factor Sox2 in serous ovarian carcinomas

Abstract P1-01-13: A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector™ enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Effects of bisphosphonates on human osteoblasts as an important constituent of the bone marrow microenvironment

Bone marrow carcinosis in breast cancer: Clinical presentation, treatment, and prognosis—A single institution review of 22 cases

Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study

Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study

The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer

Abstract P3-01-14: A nomogram to predict the likelihood of axillary non-sentinel lymph node metastases in sentinel lymph node positive primary breast cancer patients

Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167)

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167)

Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167)

Abstract P1-07-20: Developing prognostic indicators of poor outcomes in PRAEGNANT metastatic breast cancer cohort

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group

Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study

Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer

Influence of primary systemic therapy on minimal residual disease in primary breast cancer

Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial

Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry

Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics

Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry

Suchergebnisse filtern